Natriuretic Peptide (ANP) vs Thymosin Beta-4
Your heart's natural fluid and pressure regulator, helping restore balance when fluid overload strikes.
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Natriuretic Peptide (ANP)
0.025–0.050 mcg/kg/min
Thymosin Beta-4
2–5 mg
Frequency
Natriuretic Peptide (ANP)
Once daily
Thymosin Beta-4
Twice weekly
Administration
Natriuretic Peptide (ANP)
Intravenous infusion (continuous) - standard hospital delivery method
Thymosin Beta-4
Subcutaneous injection
Cycle length
Natriuretic Peptide (ANP)
Ongoing/indefinite
Thymosin Beta-4
8-12 weeks
Onset speed
Natriuretic Peptide (ANP)
Moderate (1-2 weeks)
Thymosin Beta-4
Moderate (1-2 weeks)
Evidence level
Natriuretic Peptide (ANP)
Moderate human trials (Phase 1-2)
Thymosin Beta-4
Moderate human trials (Phase 1-2)
Benefit ratings
Acute Fluid Management
Hemodynamic Stabilization
Symptom Relief
Wound Healing
Inflammation Reduction
Tissue Regeneration
Compound specifications
Natriuretic Peptide (ANP)
Molecular formula
C127H203N45O39S3
Molecular weight
3080.5 g/mol
Half-life
Approximately 15-30 minutes (IV administration)
Bioavailability
100% (intravenous administration)
CAS number
Variable depending on salt form; carperitide CAS: 120399-20-4
Thymosin Beta-4
Molecular formula
C212H350N56O78S
Molecular weight
4963
Half-life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS number
77591-33-4
Dosing compared
Natriuretic Peptide (ANP)
Intravenous
0.0125 mcg/kg/min continuous infusion
Continuous IV infusion · Up to 72 hours
Very low starting dose used in some acute heart failure cases per Japanese Circulation Society guidance [4]. Hospital-only, titrated to blood pressure.
0.025-0.050 mcg/kg/min continuous infusion
Continuous IV infusion · Up to 72 hours
Guideline low-dose range for acute heart failure; associated with better 1-year outcomes than very-low dose [4]. Requires continuous hemodynamic monitoring.
Thymosin Beta-4
Subcutaneous injection
2-5 mg (community injectable practice for 'TB-500')
Once or twice weekly · 4-6 week loading phase, then weekly maintenance
Documented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.
Topical ophthalmic (eye drops)
0.1% (1 mg/mL) RGN-259 solution, 1 drop
Several times daily (e.g. up to 5x/day) · 4 weeks
0.1% RGN-259 ophthalmic solution used in phase III neurotrophic keratopathy and dry-eye trials, applied as eye drops several times daily for ~4 weeks [5].
Intravenous injection
450-1200 mg
IV push daily for the first 3 days, then weekly · Total of 7 doses over ~5 weeks
Doses studied in the RGN-352 acute myocardial infarction clinical program, given IV after PCI [6].
Best suited for
Natriuretic Peptide (ANP)
Managing acute decompensated heart failure with fluid overload
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on managing acute decompensated heart failure with fluid overload. [8][9] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving shortness of breath caused by pulmonary congestion
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on relieving shortness of breath caused by pulmonary congestion. [8] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Lowering elevated blood pressure in emergency cardiac situations
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on lowering elevated blood pressure in emergency cardiac situations. [5][11] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing the workload on the heart during acute episodes
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on reducing the workload on the heart during acute episodes. [11][12] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Beta-4
Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions
Side effects
Natriuretic Peptide (ANP)
Common
- Mild discomfort at treatment site
- Hypotension (excessively low blood pressure) requiring close monitoring
- Headache and dizziness from sudden blood pressure changes
- Weakness and fatigue during or shortly after treatment
- Nausea and gastrointestinal discomfort
- Decreased kidney function temporarily, requiring follow-up monitoring
- Tremors or shaking sensations
- Atrial fibrillation (irregular heartbeat) in some patients
- Abdominal pain
- Injection site reactions if administered intravenously
- Renal dysfunction with prolonged use, especially in elderly patients
Serious
- Severe allergic reaction
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Safety & evidence
Natriuretic Peptide (ANP)
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Exogenous ANP demonstrates excellent safety in Phase II/III cardiac decompensation trials with rapid clearance (2-minute half-life) [6][10] providing inherent safety margins. Hypotension is the expected primary effect, managed through continuous hemodynamic monitoring and dose titration. [9][10] No serious adverse events or carcinogenicity observed in 500+ trial participants. Receptor desensitization with prolonged continuous infusion [5] requires periodic treatment breaks or dose adjustments.
Contraindications
- Severe kidney failure with very low glomerular filtration rate
- Recent or ongoing treatment with certain blood pressure medications that may cause dangerous drops in pressure
- Acute coronary syndrome or recent heart attack where vasodilation could be harmful
- Severe hypotension or cardiogenic shock without proper supportive care
- Allergies to ANP, carperitide, or any components of the pharmaceutical formulation
Thymosin Beta-4
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- Active systemic infections
- Severe immunosuppression
- Hypersensitivity to thymosin or any component
- Pregnancy (insufficient safety data)
Which is right for you?
Choose Natriuretic Peptide (ANP) if...
- Managing acute decompensated heart failure with fluid overload
- Relieving shortness of breath caused by pulmonary congestion
- Lowering elevated blood pressure in emergency cardiac situations
- Reducing the workload on the heart during acute episodes
Choose Thymosin Beta-4 if...
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation